Back to User profile » Dr Ibrahim Turkoz
Papers published by Dr Ibrahim Turkoz:
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE Studies [Corrigendum]
Sajatovic M, Doring M, Lopena OJ, Johnston K, Turkoz I, Josiah N, Obando C
Neuropsychiatric Disease and Treatment 2025, 21:1287-1288
Published Date: 27 June 2025
Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis
Hamilton JM, Johnston KL, Simples Jnr J, Turkoz I, Lim L, Antunes J, Obando C, Mattingly G
Neuropsychiatric Disease and Treatment 2025, 21:1203-1214
Published Date: 18 June 2025
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE Studies
Sajatovic M, Doring M, Lopena OJ, Johnston K, Turkoz I, Josiah N, Obando C
Neuropsychiatric Disease and Treatment 2024, 20:2227-2235
Published Date: 21 November 2024
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections
Turkoz I, Daskiran M, Starr HL, Najarian D, Lopena O, Obando C, Keenan A, Benson C, Gopal S
Neuropsychiatric Disease and Treatment 2022, 18:1927-1937
Published Date: 30 August 2022
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
Borentain S, Williamson D, Turkoz I, Popova V, McCall WV, Mathews M, Wiegand F
Neuropsychiatric Disease and Treatment 2021, 17:3459-3470
Published Date: 30 November 2021
Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
O'Donnell A, Rao S, Turkoz I, Gopal S, Kim E
Neuropsychiatric Disease and Treatment 2021, 17:1-9
Published Date: 6 January 2021
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E
Neuropsychiatric Disease and Treatment 2019, 15:731-737
Published Date: 22 March 2019
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
Li H, Li Y, Feng Y, Zhuo J, Turkoz I, Mathews M, Tan W
Neuropsychiatric Disease and Treatment 2018, 14:1107-1117
Published Date: 26 April 2018
Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
Li HF, Turkoz I, Zhang F
Neuropsychiatric Disease and Treatment 2016, 12:15-24
Published Date: 21 December 2015
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
Sliwa JK, Bossie CA, Fu D-J, Turkoz I, Alphs L
Neuropsychiatric Disease and Treatment 2012, 8:375-385
Published Date: 27 August 2012